Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 TAR-210 intravesical erdafitinib study in FGFR-altered bladder cancer
NL-OMON53522Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of erdafitinib in bladder cancer and transitional cell carcinoma (TCC) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence and severity of adverse events including dose-limiting toxicities. Planned start Mar 2022; status: withdrawn.
02
Drugs
erdafitinib
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON53522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53522.